IP Library Granted Patent US 11,926,662
Granted Patent B2
US 11,926,662 · App. 17/109,924 · Granted Mar 12, 2024

Anti-GM-CSF antibodies and uses thereof

Inventors: Zhengyi Wang (Shanghai, CN); Lei Fang (Shanghai, CN); Bingshi Guo (Shanghai, CN); Jingwu Zang (Shanghai, CN)
Assignee: I-Mab Biopharma (Hangzhou) Co., Ltd.
C07K16/24A61K39/3955A61P19/02A61P29/00A61P35/00A61P35/02A61P37/02A61P37/06C07K16/243G01N33/6863A61K2039/505C07K2317/24C07K2317/30C07K2317/33C07K2317/73C07K2317/76C07K2317/92C07K2317/94G01N2333/535
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,926,662
App. No.
17/109,924
Granted
Mar 12, 2024
Kind
B2
Abstract

Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

Claims (8)

1. A method for inhibiting production of inflammatory cytokines in a human subject in need thereof, comprising administering to the subject an antibody or antigen-binding fragment thereof that has specificity to a human granulocyte macrophage colony-stimulating factor (GM-CSF) protein and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a VH complementarity determining region (CDR) 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and the VL comprises a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6.

2. The method of claim 1 , wherein the inflammatory cytokines are selected from the group consisting of TNF, IL-6, IL-12p70, IL-23, IL-1β, and combinations thereof.

3. The method of claim 1 , wherein the subject suffers from an infection.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof further comprises a heavy chain constant region, a light chain constant region, an Fc region, or the combination thereof.

5. The method of claim 1 , wherein the antibody or fragment thereof is humanized.

6. The method of claim 1 , wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 8-17.

7. The method of claim 6 , wherein the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 19-22.

8. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 14 and the VL comprises the amino acid sequence of SEQ ID NO: 22.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2021
From: WANG, ZHENGYI; FANG, LEI; GUO, BINGSHI; ZANG, JINGWU
To: I-MAB
Reel/Frame 056919/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2021
From: I-MAB
To: I-MAB BIOPHARMA US LIMITED
Reel/Frame 056919/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2021
From: I-MAB BIOPHARMA US LIMITED
To: I-MAB BIOPHARMA CO., LTD.
Reel/Frame 056919/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2021
From: I-MAB BIOPHARMA CO., LTD.
To: I-MAB BIOPHARMA HONG KONG LIMITED
Reel/Frame 055994/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2021
From: I-MAB BIOPHARMA HONG KONG LIMITED
To: I-MAB BIOPHARMA (HANGZHOU) CO., LTD.
Reel/Frame 055994/0665 →
Priority Claims (2)
CN 201610831525.9 · Sep 19, 2016 · national
CN 201610832677.0 · Sep 19, 2016 · national
Continuity (3)
Continuation 16100063 · Aug 9, 2018
Continuation 15744734
Related Publication 20210079085A1 · Mar 18, 2021